NKGen Biotech announced that Chairman and CEO Paul Y. Song, M.D., will present on troculeucel, the company’s lead investigational program, at Biologics Manufacturing Korea 2026 in Incheon on 17-18 Sept. 2026, with the presentation scheduled for 18 Sept. at 11:00 a.m. KST.
The presentation will cover troculeucel’s use in neurodegenerative diseases, including its mechanism in reducing cerebrospinal fluid neuroinflammatory and protein biomarkers, clinical experience in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia, and the regulatory landscape in Asia.
According to the company, a copy of the presentation will be posted to its Scientific Publications section after the event.
Troculeucel is described by the company as an ex vivo expanded autologous natural killer cell immunotherapeutic and is the WHO International Nonproprietary Name for SNK01.
NKGen Biotech is a clinical-stage firm headquartered in Santa Ana, California.
